On March 27, the U.S. Food and Drug Administration (FDA) approved Zejula (niraparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors responded completely or partially to platinum-based chemotherapy. Read more
FDA approves maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
